A prospective evaluation of natriuretic peptide based referral of CHF patients in primary care - PREFER

ovartis Pharma services AG0 个研究点目标入组 1,415 人开始时间: 2016年12月15日最近更新: 2019年6月30日

试验速览

暂无简介。

•- Willing and able to provide written informed consent and accept study procedures and time schedule.
•- Age = 18 years.
•- Patients suffering from chronic heart failure whose diagnosis has been made or confirmed by a cardiologist and/or hospital physician.
•- Patients with reduced ejection fraction (LVEF = 40%).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 1600
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2400

•- Use of investigational drugs within 5 half-lives of enrollment, or within 30 days /until the expected pharmacodynamic effect has returned to baseline.
•- Major surgery in the last 3 months or planned/foreseeable major surgery or cardiac intervention during the study.
•- Cancer or other significant co-morbidities implying that the patient’s condition is unstable.
•- Comorbidities that can be associated with elevated natriuretic peptide (NP) levels, recent (less than 3 months) cerebral trauma or recent (less than 3 months) cerebrovascular incident, novel diagnosis or acute exacerbation of COPD within the last 3 months.
•- Patients who are primarily managed and regularly followed-up by a cardiologist for their HF.
•- Highly frail patients whose estimated lifespan due to comorbidities is less than 6 months.

发起方